Background
CRC, urothelial carcinoma, UC, various B-cell malignancies, RCC, gastric adenocarcinoma, chronic graft-versus-host disease, RCC
SOLID TUMOUR, UROTHELIAL CARCINOMA, COLORECTAL ADENOCARCINOMA, CHRONIC GRAFT-VERSUS-HOST DISEASE, DISEASES, RCC
Ibrutinib, a first-in-class, once-daily covalent inhibitor of Bruton’s tyrosine kinase (BTK), is approved for the treatment of various B-cell malignancies and chronic graft-versus-host disease following the failure of one or more lines of systemic therapy and remains under investigation in these settings and for other diseases [There remains an unmet need for patients with RCC, gastric adenocarcinoma (GC), and colorectal adenocarcinoma (CRC) who have progressed on previous vascular endothelial growth factor (VEGF)-targeted and mammalian target of rapamycin (mTOR) inhibitors [On this basis, we conducted a phase 1b/2 clinical study to explore the safety, tolerability, and preliminary activity of ibrutinib combination therapy in previously treated patients with advanced solid tumours, including RCC, GC, CRC, and urothelial carcinoma (UC) who had failed multiple lines of therapy. Here we report results from the RCC, GC, and CRC cohorts (UC cohorts to be reported separately).